Spots Global Cancer Trial Database for Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain
Study ID: NCT00858754
Conditions
Study Description
Brief Summary: This purpose of this study is to evaluate the safety and effectiveness of a subcutaneous (injection beneath the skin) form of methylnaltrexone in subjects who have cancer-related pain and constipation from taking opioids. The length of participation will be up to 7 weeks.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pfizer Investigational Site, Laguna Hills, California, United States
Pfizer Investigational Site, Lancaster, California, United States
Pfizer Investigational Site, Flat Rock, North Carolina, United States
Pfizer Investigational Site, Madison, Wisconsin, United States
Pfizer Investigational Site, Edmonton, Alberta, Canada
Pfizer Investigational Site, Villejuif Cedex, , France
Pfizer Investigational Site, El Palmar, Murcia/Spain, Spain
Pfizer Investigational Site, , ,
Contact Details
Name: Jeff Cohn
Affiliation: Bausch Health Americas, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
